 |
|
|
| |
Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
|
| |
| |
EASL 2023 June 21-24 Vienna
Man-Fung Yuen1, Jeong Heo2, Ronald Nahass3, Grace Wong4, Tatiana Burda5, Kalyan Ram Bhamidimarri6, Tsung-Hui Hu7, Tuan Nguyen8, Young-Suk Lim9, Chi-Yi Chen10, Stuart Gordon11, Jacinta Holmes12,
Wan-Long Chuang13, Anita Kohli14, Naim Alkhouri15, Kevin Gray16, Emily P Thi17, Elina Medvedeva16, Timothy Eley16, Karen D Sims16
1The University of Hong Kong, Hong Kong; 2Pusan National University Hospital, South Korea; 3ID Care, Hillsborough NJ, USA; 4The Chinese University of Hong Kong, Hong Kong; 5Arensia Exploratory Medicine, Chisinau, Moldova; 6University of Miami, Miami FL, USA; 7Chang Gung Memorial Hospital, Taiwan; 8Research and Education Inc., San Diego CA, USA; 9Asan Medical Center, Seoul, South Korea; 10Chia-Yi Christian Hospital, Taiwan; 11Henry Ford Hospital, Detroit MI, USA; 12St. Vincent's Hospital, Melbourne, Australia; 13Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 14Arizona Liver Health, Chandler AZ, USA; 15Arizona Liver Health, Tucson AZ, USA; 16Arbutus Biopharma, Clinical Development, Warminster PA, USA; 17Arbutus Biopharma, Discovery, Warminster PA, USA
|
| |
|
|
|
|
|
